Houjou

What Houjou does

Houjou, Inc. (株式会社ほうじょう) is a privately-held Japanese biotechnology company founded on January 6, 2020 and headquartered at the Louis Pasteur Medical Research Center in Sakyo-ku, Kyoto. The company develops and validates methodologies for in vitro gametogenesis (IVG) — the process of inducing germ cells, particularly oocytes (eggs), from pluripotent stem cells (ESCs and iPSCs) of humans, rare non-human primates, and representative mammals. Its scientific founders, Executive Directors Mitinori Saitou and Katsuhiko Hayashi, are globally recognized pioneers of IVG research and have already demonstrated proof-of-principle in mice; the company is now working to extend the approach to humans and other mammals.

The underlying technology is a cell biology platform rather than a software product: it uses proprietary induction protocols to differentiate pluripotent stem cells into functional germ cells in vitro, with downstream relevance to infertility treatment, regenerative medicine, and endangered species conservation. Houjou's stated business activity is the development of cell technologies for endangered species protection, regenerative medicine, and infertility treatment, including the preservation and distribution of such cells. There are no named commercial products, no disclosed pricing, no marketing or distribution channels, and no announced partnerships, customers, or revenue.

The company is led by President & CEO Masakazu Kobayashi (小林正和), with the two founding scientists serving as Executive Directors and Shusei Kamata as Auditor. It is privately held with no disclosed investors, parent entity, funding rounds, headcount, or public listing. Operations are concentrated in Japan, with no global footprint claims. As a result, Houjou is best characterized today as a founder-anchored, science-stage biotech commercializing a frontier reproductive biology platform, with commercialization model and revenue mechanics still undefined.

Name

Houjou

Legal name

株式会社ほうじょう（Houjou, Inc.）

Website

https://houjou-inc.com

Company type

Private

Founded year

2020

Operating status

Operating

Short description

Houjou is a Kyoto-based, privately-held Japanese biotechnology company developing in vitro gametogenesis (IVG) technology to create oocytes from human and mammalian pluripotent stem cells, serving regenerative medicine, infertility treatment, and endangered species conservation applications.

Ownership category

akta.pro rank

Product category

Reproductive Biotechnology

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro industry

PRIMARYHLAAAGAA

Stem Cell–Based Regenerative Therapies

Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

SECONDARYHLAAABAE

Stem Cell Therapies (MSC/iPSC/HSC-derived)

Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

SECONDARYHLAAABAL

Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)

Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

• In vitro gametogenesis
• Reproductive biotechnology
• Stem cell research
• Oocyte generation
• Regenerative medicine

Headquarters

HQ city

Kyoto

HQ country

Japan

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Core offering

Houjou develops and validates methodologies for inducing germ cells, particularly oocytes, from human and other species pluripotent stem cells (ESCs and iPSCs) using in vitro gametogenesis (IVG). The company conducts cell technology development, preservation, and distribution targeted at endangered species protection, regenerative medicine, and infertility treatment. The core technology builds on proof-of-principle IVG demonstrated in mice and ongoing work to extend it to humans and other mammals.

Product overview

Houjou is a biotechnology company developing in vitro gametogenesis (IVG) technology — a platform for inducing germ cells, particularly oocytes, from human and other species pluripotent stem cells (PSCs). The company focuses on addressing global challenges including infertility, species conservation, and food supply through the generation of mature oocytes from stem cells. No distinct named products or modules are listed; the company operates as a research and technology development organization offering cell technology services for endangered species protection, regenerative medicine, and infertility treatment, including cell preservation and distribution.

Differentiator

Problem solved

Functional benefit

Products and services

• In Vitro Gametogenesis (IVG) Research and Development
• Cell Preservation and Distribution Services

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Recent moves4 records

Expansion highlights3 records

Direct peers

• Gameto: Biotech applying cell engineering to ovarian and reproductive biology, with programs in fertility and menopause. Comparable to Houjou as a cell-engineering platform company targeting reproductive medicine.
• Ivy Natal: Cell-based fertility treatment company developing lab-grown egg and sperm cells from stem cells. Closely overlaps with Houjou's IVG-to-gamete pipeline and target customer (IVF clinics).
• Conception Bio: US-based biotechnology company also pursuing in vitro gametogenesis to derive human eggs from stem cells. Most directly comparable to Houjou in technology, target application (human fertility), and category.

Emerging players

• ReproNovo: Reproductive medicine biotech developing therapies for infertility and women's health. Comparable to Houjou in target indication (human infertility) even though it is not focused on IVG-derived gametes.
• Cytovia Therapeutics: Develops iPSC-derived NK and gene-edited cell therapies for oncology. Shares the iPSC-as-source-material foundation with Houjou but operates in a different therapeutic vertical (immuno-oncology).

Broad incumbents

• Lineage Cell Therapeutics: Clinical-stage cell therapy company developing allogeneic cell transplant therapies across multiple indications. Comparable as a broader cell therapy platform player, but does not focus on germ cells or IVG.

Regional players

• Healios K.K. Japan-based cell therapy company commercializing stem cell-derived products. Comparable to Houjou as a Japanese regenerative medicine company using stem cell platforms, but focused on somatic rather than germ cell applications.

Others

• OvaScience (historical): Historical public company that pursued egg-related biology for fertility treatment before winding down. Useful as a historical analog for commercialization challenges in the oocyte science space.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Houjou